Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 36
- Registration Number
- NCT06714864
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
- Conditions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- CorMedix
- Registration Number
- NCT06707480
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 806
- Registration Number
- NCT02651428
- Locations
- 🇺🇸
Diagnostic Clinic of Houston, Houston, Texas, United States
🇺🇸Riverside Nephrology Physicians/Van Buren Dialysis center, Riverside, California, United States
🇺🇸North America Research Institute, San Dimas, California, United States
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- CorMedix
- Registration Number
- NCT01391520
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 60
- Registration Number
- NCT01146925
- Locations
- 🇺🇸
Providence Hospital, Southfield, Michigan, United States
🇺🇸Ohio Health Research Institute, Columbus, Ohio, United States
🇺🇸Cardiovascular Catheterization Labs at Fairfield, Fairfield, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath